ASLAN Pharmaceuticals Pte Ltd
http://www.aslanpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ASLAN Pharmaceuticals Pte Ltd
Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives
Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.
After Long Regulatory Run, Sanofi’s Dupixent Set To Transform India AD Market
Sanofi has received a go-ahead in India for dupilumab in atopic dermatitis with a trial waiver. An India-specific price, local real-world effectiveness and safety study and compelling data are expected to give it an edge over competition in the wings, including Pfizer’s Cibinq.
Aslan Bullish On Once-Monthly Dosing For Eblasakimab In Atopic Dermatitis
A Phase IIb trial testing the IL-13 inhibitor in atopic dermatitis demonstrated solid efficacy when dosed once every four weeks, but the market is competitive and dominated by Sanofi/Regeneron’s Dupixent.
Deal Watch: Tourmaline Will Pursue Its Thyroid Eye Disease Ambitions Following Merger With Talaris
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice